ICECAP: Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients
A multicenter, randomized, adaptive allocation clinical trial to determine if increasing durations of induced hypothermia are associated with an increasing rate of good neurological outcomes and to identify the optimal duration of induced hypothermia for neuroprotection in comatose survivors of cardiac arrest.
More information can be found at:
PRECICECAP: PREcision Care In Cardiac ArrEst - ICECAP
The study is set up to discover novel biomarker signatures of post cardiac arrest brain and extracerebral organ failure that predict treatment responsiveness and long-term recovery.
More information can be found at:
POST-ICECAP: Patterns Of Survivors’ Recovery Trajectories in the ICECAP trial
POST-ICECAP is an ancillary study to the NINDSNHLBI funded ‘Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients’ trial, conducted within the NIH Strategies to Innovate Emergency Care Clinical Trials Network. POST-ICECAP will describe the extent of improvement or deterioration in functional, cognitive, and health related quality of life outcomes within ÂÃ months after an out of hospital cardiac arrest ¥OHCA¦. It will estimate the prospective associations of clinical interventions, rehabilitation, and social determinants with those dimensions of recovery in a large, well characterized, racially ethnically diverse, US representative cohort of OHCA patients.
More information can be found at:
BOOST3
BOOST3 is a randomized clinical trial that compares two strategies for monitoring and treating traumatic brain injury (TBI) patients in the ICU. One strategy uses both intracranial pressure (ICP) and brain tissue oxygen (PbtO2) as treatment guides, while the other relies on ICP alone. Both strategies are part of standard care, but it is unclear if one is more effective. The trial will evaluate whether one method provides safer and more effective treatment by adjusting medications, fluids, ventilator settings, blood transfusions, and other medical care.
More information cat be found at :
ARREST Pneumonia: Arrest RESpiraTory Failure From PNEUMONIA
This research study seeks to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.
More information can be found at:
- Study Details | ARrest RESpiraTory Failure From PNEUMONIA | ClinicalTrials.gov
- ARREST Pneumonia NIH RePORTER
FASTEST: rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time Trial.
This research study is investigating the use of Recombinant Factor VIIa, a medication commonly used to treat and prevent bleeding, to see if it can improve outcomes after a stroke caused by bleeding in the brain.
More information can be found at:
- Study Details | Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial | ClinicalTrials.gov
- FASTEST NIH RePORTER
LIBREXIA: A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack. *Ischemic stroke or TIA*
To study the efficacy of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack.
More information can be found at:
SISTER: Strategy for Improving Stroke Treatment Response
SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.
More information can be found at:
- Study Details | Strategy for Improving Stroke Treatment Response | ClinicalTrials.gov
- SISTER NIH RePORTER